Shares of ResMed Inc. (NYSE:RMD – Get Free Report) passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $231.87 and traded as low as $228.33. ResMed shares last traded at $230.7630, with a volume of 3,445,161 shares trading hands.
Key ResMed News
Here are the key news stories impacting ResMed this week:
- Positive Sentiment: Quarterly results exceeded expectations. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share versus the $2.67 consensus estimate, while revenue rose 5.9% year over year to $1.41 billion, ahead of the $1.39 billion forecast. ResMed fiscal first-quarter results
- Positive Sentiment: Profitability and demand trends improved. Sustained demand for sleep devices, productivity gains and gross-margin expansion supported the earnings beat. EPS increased from $2.55 in the year-ago quarter, and ResMed reported a 26.94% net margin. ResMed earnings and margin growth
- Positive Sentiment: Analysts raised price targets. RBC increased its target from $262 to $288 and assigned an “outperform” rating. KeyCorp raised its target from $267 to $277 with an “overweight” rating, while Wells Fargo lifted its target from $215 to $250 and maintained “equal weight.” Citigroup raised its target from $240 to $270 but retained a “neutral” rating. Analyst target changes
- Neutral Sentiment: ResMed declared a quarterly dividend of $0.66 per share, or $2.64 annualized, representing an approximately 1.1% yield. The dividend supports shareholder returns but is unlikely to be the primary near-term stock catalyst.
- Negative Sentiment: Full-year guidance was unchanged. The lack of an outlook increase may have disappointed investors who expected the earnings beat and improving margins to result in raised expectations. The neutral ratings from Citigroup and Wells Fargo may also limit the impact of the higher price targets. ResMed maintains prior guidance
Analysts Set New Price Targets
Several research firms have recently issued reports on RMD. UBS Group reaffirmed a “buy” rating and issued a $300.00 price objective on shares of ResMed in a research note on Tuesday, July 21st. Citigroup lifted their target price on shares of ResMed from $240.00 to $270.00 and gave the stock a “neutral” rating in a research report on Friday. Wells Fargo & Company boosted their target price on shares of ResMed from $215.00 to $250.00 and gave the stock an “equal weight” rating in a report on Friday. Royal Bank Of Canada raised their price target on shares of ResMed from $262.00 to $288.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Rothschild & Co Redburn initiated coverage on shares of ResMed in a report on Wednesday, August 19th. They set a “neutral” rating and a $230.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $253.69.
Read Our Latest Stock Report on ResMed
ResMed Price Performance
The company has a fifty day moving average of $231.87 and a 200 day moving average of $225.43. The firm has a market capitalization of $32.45 billion, a P/E ratio of 21.02, a PEG ratio of 1.55 and a beta of 0.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.10 and a quick ratio of 2.42.
ResMed (NYSE:RMD – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $0.24. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.39 billion. ResMed had a net margin of 27.79% and a return on equity of 25.90%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.55 EPS. Sell-side analysts predict that ResMed Inc. will post 12.11 earnings per share for the current year.
ResMed Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be given a dividend of $0.66 per share. The ex-dividend date is Thursday, November 12th. This represents a $2.64 annualized dividend and a dividend yield of 1.1%. ResMed’s dividend payout ratio is 25.31%.
Insider Buying and Selling
In related news, Director Peter Farrell sold 8,000 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total value of $1,800,000.00. Following the transaction, the director owned 52,773 shares in the company, valued at $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Michael Rider sold 400 shares of the company’s stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $255.00, for a total transaction of $102,000.00. Following the sale, the general counsel directly owned 12,318 shares in the company, valued at $3,141,090. This trade represents a 3.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,343 shares of company stock valued at $5,396,098 over the last quarter. Insiders own 0.58% of the company’s stock.
Institutional Investors Weigh In On ResMed
Several institutional investors and hedge funds have recently made changes to their positions in RMD. Bell Investment Advisors Inc bought a new stake in ResMed in the second quarter worth approximately $26,000. Trust Co. of Vermont bought a new position in shares of ResMed during the 2nd quarter worth approximately $39,000. Kelleher Financial Advisors bought a new position in shares of ResMed during the 2nd quarter worth approximately $47,000. Provenance Wealth Advisors LLC bought a new position in shares of ResMed during the 3rd quarter worth approximately $55,000. Finally, Harbor Investment Advisory LLC grew its position in shares of ResMed by 82.6% during the 2nd quarter. Harbor Investment Advisory LLC now owns 409 shares of the medical equipment provider’s stock worth $80,000 after buying an additional 185 shares during the period. Institutional investors own 54.98% of the company’s stock.
About ResMed
ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.
ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.
Featured Stories
- Five stocks we like better than ResMed
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
